Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022022709 - SIRPα-FC FUSION PROTEIN

Publication Number WO/2022/022709
Publication Date 03.02.2022
International Application No. PCT/CN2021/109824
International Filing Date 30.07.2021
IPC
C07K 14/47 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
A61K 38/17 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Applicants
  • 三生国健药业(上海)股份有限公司 SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. [CN]/[CN]
Inventors
  • 赵杰 ZHAO, Jie
  • 黄浩旻 HUANG, Haomin
  • 朱祯平 ZHU, Zhenping
Agents
  • 上海一平知识产权代理有限公司 XU&PARTNERS, LLC.
Priority Data
202010748225.030.07.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) SIRPα-FC FUSION PROTEIN
(FR) PROTÉINE DE FUSION SIRPα-FC
(ZH) 一种SIRPα-Fc融合蛋白
Abstract
(EN) Disclosed is a SIRPα-Fc fusion protein. The fusion protein comprises a SIRPαD1 domain variant and an immunoglobulin Fc region. The fusion protein of the present invention has the potential to treat diseases related to the SIRPα-CD47 signal pathway.
(FR) L'invention concerne une protéine de fusion SIRPα-Fc. La protéine de fusion comprend un variant de domaine SIRPαD1 et une région Fc d'immunoglobuline. La protéine de fusion de la présente invention a le potentiel de traiter des maladies associées à la voie de signalisation SIRPα-CD47.
(ZH) 本发明公开了SIRPα-Fc融合蛋白。所述融合蛋白包括SIRPαD1结构域变体和免疫球蛋白Fc区。本发明的融合蛋白具有治疗SIRPα-CD47信号通路相关疾病的潜力。
Related patent documents
Latest bibliographic data on file with the International Bureau